Elanco Animal Health Incorporated (FRA:5EA)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.77B +26.4% |
| Revenue (ttm) | 4.39B +12.0% |
| Net Income | -174.18M |
| EPS | -0.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 18.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 19.59 |
| Previous Close | 19.76 |
| Day's Range | 19.59 - 19.59 |
| 52-Week Range | 15.46 - 23.15 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
News
Elanco to Participate in BofA Securities Global Healthcare Conference 2026
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
Elanco Animal Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Pet health and farm animal markets are experiencing robust growth, driven by innovation, omni-channel expansion, and resilient demand. Differentiated products like Zenrelia, Quattro, and Befrena are gaining share, while margin improvements and a strong pipeline support long-term growth through 2027 and beyond.
Expanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low d...
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.
Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ --...
Elanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra pro...
Elanco CEO on Boosted Forecast, Surge in Tick Bites
Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent...
Elanco Animal Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 8% organic revenue growth, margin expansion, and strong innovation-driven gains, especially from Zenrelia and Credelio Quattro. Full-year guidance was raised for revenue, EBITDA, and EPS, with continued investment in launches and productivity initiatives.
Elanco Animal Health Earnings release: Q2 2026
Elanco Animal Health released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Elanco Animal Health Slides: Q2 2026
Elanco Animal Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Elanco Animal Health Quarterly report: Q2 2026
Elanco Animal Health has published its Q2 2026 quarterly earnings report on August 5, 2026.
Elanco Animal Health Reports Second Quarter 2026 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% or...
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /...
Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Kills Ticks¹ Faster² than Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) and NexGard® Plus (afoxolaner, moxidectin, and pyrantel chewable tablets)
Published Data Shows that the Active Ingredient, Lotilaner, in Credelio Quattro: Kills existing black-legged tick (Ixodes scapularis) infestations faster2 than leading competitors, within just 8 hours...
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct...
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: E...
Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine...
Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'
Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.
Confirmed screwworm case in Texas sends two biotech stocks higher
Options volume is surging for Zoetis as traders look for potential stock market winners in light of a screwworm case in Texas.
Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first conf...
New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience
INDIANAPOLIS, June 3, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN), a global leader in animal health, today released new consumer research showing pet owners continue to priorit...
Elanco Animal Health Transcript: 46th Annual William Blair Growth Stock Conference
The company is leveraging a robust innovation pipeline and diversified global presence to drive mid-single-digit revenue growth, high single-digit EBITDA, and over $1 billion in free cash flow through 2028. U.S. pet health is a key growth area, with new product launches and resilient consumer demand supporting strong financial guidance.
Elanco Animal Health Slides: 46th Annual William Blair Growth Stock Conference
Elanco Animal Health has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Elanco Animal Health Transcript: Stifel Jaws & Paws Conference 2026
The conference highlighted robust growth in animal health, driven by innovation in pet and farm segments, resilient pricing, and strong product launches like Zenrelia and Befrena. Strategic focus remains on operational efficiency, disciplined capital allocation, and a robust pipeline for future growth.